Treatment patterns, outcomes and testing in EGFRm NSCLC patients with EGFR TKI 1L across Europe (REFLECT)

Trial Identifier: D5162R00009
Sponsor: AstraZeneca
NCTID:: NCT04031898
Start Date: May 2019
Primary Completion Date: December 2019
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Bulgaria Plovdiv, Bulgaria, 4000
Bulgaria Sofia, Bulgaria, 1756
Bulgaria Wien, Bulgaria, 1140